PVLA
Palvella Therapeutics, Inc
NASDAQ: PVLA · HEALTHCARE · BIOTECHNOLOGY
$130.17
+0.54% today
Updated 2026-05-06
Market cap
$1.82B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.70
Dividend yield
—
52W range
$20 – $151
Volume
0.3M
Palvella Therapeutics, Inc (PVLA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-92.10%
ROA
-32.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $12.43M | $66196.00 | — | 4.46% | 0.53% |
| 2014 | $5.37M | $-9.85M | — | -134.17% | -183.60% |
| 2015 | $2.93M | $-14.06M | — | -446.15% | -479.50% |
| 2016 | $5.83M | $-22.80M | — | -390.31% | -391.00% |
| 2017 | $25.27M | $-17.65M | — | -57.74% | -69.82% |
| 2018 | $29.10M | $-26.75M | — | -105.94% | -91.93% |
| 2019 | $46.28M | $-25.47M | — | -58.68% | -55.03% |
| 2020 | $29.32M | $-37.23M | 100.00% | -115.68% | -126.97% |
| 2021 | $31.42M | $-45.74M | 92.46% | -164.97% | -145.58% |
| 2022 | $25.90M | $-33.28M | 89.27% | -167.84% | -128.47% |
| 2023 | $0.00 | $18.69M | — | — | — |
| 2024 | $0.00 | $-17.43M | — | — | — |
| 2025 | $0.00 | $-41.72M | — | — | — |